… and non-specific immunomodulating agents, including … in the management of severe
COVID-19, and their impact on … in two COVID-19 patients, and required drug discontinuation […

… with SARS-CoV and the risk of severe lung injury and thrombosis [60], we think the IVIG
option should be carefully analyzed before its use in severe COVID-19 patients. In addition, the …

… These characteristics are favourable given that duration of use in patients with COVID-19
should be short term. Ruxolitinib, a JAK 1/2 inhibitor, received US Food and Drug …

… common complications of COVID-19 patients, particularly … from COVID-19 [2]. Here, we are
going to summarize the existing immunotherapeutic strategies for severe COVID-19 patients …

… of immunomodulatory drugs has been considered to reduce the mortality rate in COVID-19
patients. In … pivotal immunomodulatory and immunosuppressant agents pertaining to different …

… of the immunomodulatory drugs used to manage COVID-19. A … the efficacy of the
immunomodulatory agents, including … -purification therapy, in COVID-19 patients. The data were …

… disruption [2,23]; COVID-19 patients with a previous history of … analysis of COVID-19 effects
reported that patients with a … complications of COVID-19 compared to patients without any …

… of patients treated with or without immunomodulatory drugs. Four hundred and eleven
patients who were diagnosed with COVID-19 … Thirty of these patients had ADs (figure 1). In the …

… comparing groups of IM drugs and their outcomes in resource-limited settings. It also provides
a wide spectrum of demographic data of critical COVID-19 patients from our country and …

… French doctors conducted an open-label non-randomized clinical trial, and this study
reported that 20 patients with COVID-19 who received hydroxychloroquine treatment showed …